Serology
Research Lines
Content with Investigacion .
Virus entéricos
1. Vigilancia microbiológica y epidemiológica a nivel nacional de las infecciones causadas por enterovirus y parechovirus y de los casos de parálisis flácida aguda en menores de 15 años. Caracterización, asociación clínica y epidemiología molecular.
2. Investigación de los enterovirus y parechovirus que causan infecciones neurológicas y sistémicas severas en población pediátrica. Estudio de los factores virológicos implicados en la patogenicidad.
3. Estudio virológico de muestras ambientales (aguas residuales y tratadas para consumo) de la CAM.
4. Estudio virológico (diagnóstico y caracterización) de las infecciones gastrointestinales causadas por virus (norovirus, rotavirus y otros). Epidemiología molecular y caracterización de brotes.
Investigación y vigilancia de los poliovirus y la poliomielitis
El Laboratorio de Enterovirus (actualmente de Virus Entéricos) del CNM fue designado Laboratorio Nacional de Poliovirus en 1998 y desde entonces es certificado anualmente por la OMS, como parte del Plan Global de Erradicación de la Poliomielitis. Es responsable, junto a 3 laboratorios primarios en 3 CCAA, de la vigilancia de la poliomielitis a nivel nacional, estudiando e investigando (clínica, epidemiológica y virológicamente) todos los casos compatibles, incluidos los de parálisis flácida aguda en menores de 15 años (enfermedad de notificación obligatoria) para descartar la presencia y circulación de poliovirus en España.
Además, desde 1999 (y gracias a un convenio con el CYII) posee toda la infraestructura y metodología necesaria para realizar vigilancia medioambiental en aguas, tanto para medir la calidad de las aguas potables de ETAP, como para monitorizar la excreción de virus por parte de la población con el estudio de la presencia de poliovirus y otros enterovirus en aguas residuales de EDAR. Esto ha permitido que, a partir de marzo de este año, se estén realizando, además, ensayos de presencia de SARS-CoV-2 en las muestras procedentes de diferentes EDAR situadas en la CAM.
Investigación y referencia en infecciones por enterovirus y parechovirus
El Laboratorio también es Laboratorio de Referencia para las infecciones por Enterovirus y Parechovirus realizando: 1) el diagnostico virológico en muestras clínicas; 2) la caracterización de todos los enterovirus y parechovirus detectados (Programa de Vigilancia Microbiológica del CNM); 3) el desarrollo, mantenimiento y transferencia de métodos de diagnóstico y tipado, tanto moleculares como de cultivo viral; y 4) la investigación para profundizar en el conocimiento de aquellos virus implicados en casos de excepcional importancia clínica o epidemiológica. La larga experiencia del grupo en la propagación de cultivos virales de enterovirus y en técnicas celulares y moleculares de caracterización, ha permitido que el CNM posea una amplia colección de cepas, muy valiosa para la investigación de estos virus.
Investigación y referencia en infecciones gastrointestinales causadas por virus
Desde 2016, el laboratorio realiza: 1) el diagnostico virológico de Norovirus, Rotavirus, Adenovirus 40/41, Astrovirus y otros virus productores de gastroenteritis aguda en muestras clínicas; 2) el genotipado de los virus detectados y la caracterización de brotes; 3) el desarrollo y mantenimiento de métodos de diagnóstico y genotipado; y 4) la investigación básica y epidemiológica de aquellos virus de mayor importancia clínica.
Research projects
Content with Investigacion .
Proyectos de investigación financiados en los últimos 5 años
- Investigación de las infecciones neurológicas graves en niños causadas por enterovirus emergentes en España: EV-A71 y EV-D68 (PI18CIII/00017). Financiación: ISCIII. 2019-2021. IP: M. Cabrerizo
- Metagenomic sequencing to identify viral etiologies in undiagnosed cases of meningitis and encephalitis (PI20CIII/00005). Financiación: ISCIII. 2021-2023. IP: M.D. Fernández-García
- Investigación en infecciones por enterovirus y parechovirus que causan patologías neurológicas y sistémicas graves en población infantil (PI15CIII/00020). Financiación: ISCIII. 2016-2019. IP: M. Cabrerizo
- Aplicación de la secuenciación masiva para el diagnóstico de infecciones neurológicas de origen vírico no filiadas (PI-0216-2019). Financiación: Junta de Andalucía, Consejería de Salud y Familias. 2019-2021. IP: M.D. Fernández-García (2019)/ Ana Belen Pérez-Jiménez (2020-21)
- Epidemiología y patogenia molecular de los enterovirus y parechovirus asociados a sepsis e infecciones neurológicas en población infantil en España (PI12/00904). Financiación: ISCIII. 2013-2016. IP: M. Cabrerizo
Otros proyectos de investigación relevantes en los que ha colaborado o colabora el grupo
- Dinámica de colonización e infección por E. coli enteroagregativo en poblaciones pediátricas y su asociación con la composición de la microbiota intestinal mediante análisis metagenómico (PI18CIII/00043). Financiación: ISCIII. 2019-2021. IP: S. Sánchez
- Paving the way for implementing a syndromic diagnostic scheme at the CNM for the diagnosis of diarrhoea-causing pathogens in stool samples based on molecular and metagenomics methods (PI19CIII/00029). Financiación: ISCIII. 2020-2022. IP: D. Carmena
- Engineering lactobacilli for intranasal immunization against the emerging enterovirus D68 (EV-D68) infections and prevention of acute flaccid myelitis. Financiación: ESCMID. 2019-2020. IP: M.C. Póvoa-Cabral
- Análisis epidemiológico y virológico de los agentes virales incluidos en la vacuna triple vírica: nuevos retos (PI15CIII/00023). Financiación: ISCIII. 2016-2019. IP: F. de Ory/A. Fernández
- Epidemiología general y molecular de la hepatitis E en España: ¿una zoonosis emergente? (PI080865). Financiación: ISCIII. 2009-2012. IP: M. Fogeda
- Etiología de las meningitis y encefalitis víricas en España (PI07/90154). Financiación: ISCIII. 2008-2010. IP: F. de Ory
- Investigation of the dynamics and geography of the spread of recombinant forms of human enteroviruses (WT081173MA). Financiación: Wellcome Trust. 2007-2010. IP: P. Simmonds.
Convenios
- Servicios para la realización de estudios virológicos previstos en el agua procedentes para Canal de Isabel II-Gestión (MVP-207/18). Financiación: Canal de Isabel II. 2018-2021. IP: M. Cabrerizo
- Análisis virológico en muestras de aguas procedentes del Canal de Isabel II (MVI-1005/99). Financiación: Canal de Isabel II. 2016-2017. IP: M. Cabrerizo
Publications
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Vigón L, Martínez-Román P, Rodríguez-Mora S, Torres M, Puertas MC, Mateos E, Salgado M, Navarro A, Sánchez-Conde M, Ambrosioni J, Cervero M, Wyen C, Hoffmann C, Miró JM, Alcamí J, Podzamczer D, García-Gutiérrez V, Martínez-Picado J, Briz V, Rosa López-Huertas M, Planelles V, Coiras M (AC). Biochem Pharmacol. 2021 Oct;192:114666. doi: 10.1016/j.bcp.2021.114666. PMID: 34186065.
PUBMED DOIT-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
1. Aragoneses-Fenoll L, Ojeda G, Montes-Casado M, Acosta-Ampudia Y, Dianzani U, Portolés P, Rojo JM. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response. Front. Immunol. 2018 Feb 27;9:332.
PUBMED DOIETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
2. Aragoneses-Fenoll L, Montes-CasadoM, Ojeda G, Acosta YY, Herranz J, Martínez S, Blanco-Aparicio C, Criado G, Pastor J, Dianzani U, Portolés P, Rojo JM. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem. Pharmacol. 2016 Apr 15;106:56-69. Epub 2016 Feb 13.
PUBMED DOISuppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75.
3. Acosta YY, Montes-Casado M, Aragoneses-Fenoll L, Dianzani U, Portoles P, Rojo JM. Suppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75. Int. J. Immunopathol. Pharmacol. 2014 Jan-Mar;27(1):53-67.
PUBMED DOIEffects of 3D nanocomposite bioceramic scaffolds on the immune response
4. Cicuendez M., Portolés P., Montes-Casado M., Izquierdo-Barba I., Vallet-Regı M., and Portolés M.T. Effects of 3D nanocomposite bioceramic scaffolds on the immune response. J. Mater. Chem. B, 2014, 2 (22), 3469-3479.
DOICharacteristics of TCR/CD3 complex CD3 chains of regulatory CD4+ T (Treg) lymphocytes: Role in Treg differentiation in vitro and impact on Treg in vivo.
5. Rojo, J. M., G. Ojeda, Y. Y. Acosta, M. Montes-Casado, G. Criado, and P. Portoles. Characteristics of TCR/CD3 complex CD3 chains of regulatory CD4+ T (Treg) lymphocytes: Role in Treg differentiation in vitro and impact on Treg in vivo. J. Leukoc. Biol. 2014, 95 (3): 441-450.
PUBMED DOIDissociation of actin polymerization and lipid raft accumulation by ligation of the Inducible Costimulator (ICOS, CD278)
6. Y. Acosta, G. Ojeda, M. P. Zafra, I. Seren-Bernardone, A. Sánchez, U. Dianzani, P. Portolés y J. M. Rojo. Dissociation of actin polymerization and lipid raft accumulation by ligation of the Inducible Costimulator (ICOS, CD278). Inmunología, 2012, 31 (1): 4-12.
DOIComplement regulatory protein Crry/p65 costimulation expands natural Treg cells with enhanced suppressive properties in proteoglycan-induced arthritis.
7. Ojeda G., Pini E., Eguiluz C., Montes-Casado M., Broere F., van Eden W., Rojo J.M., and Portolés P. Complement regulatory protein Crry/p65 costimulation expands natural Treg cells with enhanced suppressive properties in proteoglycan-induced arthritis. Arthritis Rheum. 2011 Jun;63(6):1562-72.
PUBMED DOIBiased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278)
8. Acosta Y.Y., Zafra M.P., Ojeda G., Bernardone I.S., Dianzani U., Portolés P., Rojo J.M. Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278). Cell. Mol. Life Sci. 2011 Sep;68(18):3065-79.
PUBMED DOIStructure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.
5. Mas V, Rodriguez L, Olmedillas E, Cano O, Palomo C, Terron MC, et al. Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathog. 2016;12(9):e1005859.
PUBMED DOIEssential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. Eur J Clin Microbiol Infect Dis. 2019 Sep
Bongomin F, Govender NP, Chakrabarti A, Robert-Gangneux F, Boulware DR, Zafar A, Oladele RO, Richardson MD, Gangneux JP, Alastruey-Izquierdo A, Bazira J, Boyles TH, Sarcarlal J, Nacher M, Obayashi T, Worodria W, Pasqualotto AC, Meya DB, Cheng B, Sriruttan C, Muzoora C, Kambugu A, Rodriguez Tudela JL, Jordan A, Chiller TM, Denning DW. Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1581-1584. doi: 10.1007/s10096-019-03600-4. PMID: 31175479.
PUBMED DOIGodet C, Alastruey-Izquierdo A, Flick H, Hennequin C, Mikilps-Mikgelbs R, Munteanu O, Page I, Seidel D, Salzer HJF. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother. 2018
Godet C, Alastruey-Izquierdo A, Flick H, Hennequin C, Mikilps-Mikgelbs R, Munteanu O, Page I, Seidel D, Salzer HJF. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother. 2018 Feb 1;73(2):280-286. doi: 10.1093/jac/dkx390. PMID: 29126309.
PUBMED DOIGenetic Characterization of Brucella spp.: Whole Genome Sequencing-Based Approach for the Determination of Multiple Locus Variable Number Tandem Repeat Profiles
Pelerito A, Nunes A, Grilo T, Isidro J, Silva C, Ferreira AC, Valdezate S, Núncio MS, Georgi E, Gomes JP. (2021) Genetic Characterization of Brucella spp.: Whole Genome Sequencing-Based Approach for the Determination of Multiple Locus Variable Number Tandem Repeat Profiles. 2021. Front Microbiol. 12;12:740068
PUBMED DOISaezia sanguinis gen. nov., sp. nov., a Betaproteobacteria member of order Burkholderiales, isolated from human blood
Medina-Pascual MJ, Monzón S, Villalón P, Cuesta I, González-Romo F, Valdezate S. (2020). Saezia sanguinis gen. nov., sp. nov., a Betaproteobacteria member of order Burkholderiales, isolated from human blood. Int J Syst Evol Microbiol.70:2016-25.
PUBMED DOIDynamics of a Sporadic Nosocomial Acinetobacter calcoaceticus-Acinetobacter baumannii Complex Population
Villalón P, Ortega M, Sáez-Nieto JA, Carrasco G, Medina-Pascual MJ, Garrido N, Valdezate S. (2019). Dynamics of a Sporadic Nosocomial Acinetobacter calcoaceticus-Acinetobacter baumannii Complex Population. 2019. Front Microbiol. 22;10:593
PUBMED DOIEpidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain.
Valdezate S, Garrido N, Carrasco G, Medina-Pascual MJ, Villalón P, Navarro AM, Saéz-Nieto JA. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother. 2017;72(3):754-761.
PUBMED DOIPaenibacillus spp. isolated from human and environmental samples in Spain: detection of 11 new species.
Sáez-Nieto JA, Medina-Pascual MJ, Carrasco G, Garrido N, Fernandez-Torres MA, Villalón P, Valdezate S. Paenibacillus spp. isolated from human and environmental samples in Spain: detection of 11 new species. New Microbes New Infect. 2017. 24;19:19-27.
PUBMED DOIIncrease in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis.
Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. (2015) Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. ;21(2):150-6
PUBMED DOIGenomic Background and Phylogeny of cfiA-Positive Bacteroides fragilis Strains Resistant to Meropenem-EDTA
Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. (2015) Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. ;21(2):150-6.
PUBMED DOIContent with Investigacion .
-
Concepción Casado Herrero
Tenure Scientist of Public Research Organizations (OPIs)
ORCID code: 0000-0003-3412-2877
-

Javier García Pérez
Investigador Doctor
ORCID code: 0000-0001-7551-7803
Graduated in Biochemistry (1999) and Molecular Biology (2000) from the Autonomous University of Madrid (UAM), he obtained a predoctoral fellowship “ISCIII” in the AIDS Immunopathology laboratory, where he developed new techniques based on recombinant viruses. His doctoral thesis focused on the application of this technological development to the study of the replicative capacity of HIV-1 and its resistance to antiretroviral drugs, obtaining the degree of Doctor of Science from the UAM in 2007.
Thanks to a short postdoc in 2008 and several stays between 2009 and 2015 at the Viral Pathogenesis Unit of the Institut Pasteur in Paris he extended his training in the study of HIV-1 envelope and tropism. Between 2015 and 2019 he rejoins the AIDS Immunopathology Unit at ISCIII, focusing his work on the study of the functional capacity of founder viruses, as well as variants of the virus with interest in Public Health due to its recent expansion in our country. He is currently leading a project on the study of a mutation in transportin 3 observed in patients with a very rare muscular dystrophy (LGMDD2) that confers protection against HIV-1 infection.
During the last 5 years he combines this activity in HIV-1 with the participation and leadership of different clinical trials and studies investigating the immunity generated in people vaccinated against SARS-CoV-2 infection.
Since 2024 he is a “Investigador Doctor fuera de Convenio” at the Spanish National Centre of Microbiology and he currently coordinates together with Dr. Francisco Díez Fuertes the AIDS Immunopathology Unit.
-
Miguel Thomson
Research Professor. Head of Unit
-

Eloisa Yuste Herranz
Staff Scientist
ORCID code: 0000-0002-9484-9974
She holds a Bachelor's and a Ph.D. in Biological Sciences from the Complutense University of Madrid. She completed her first postdoctoral stay (1998–2001) at the “Severo Ochoa” Molecular Biology Center (Madrid). In 2001, she undertook a second postdoctoral stay at Harvard Medical School (USA), where she was promoted to Associate Researcher in 2005.
In 2008, she joined the August Pi i Sunyer Biomedical Research Institute (Barcelona) as a Ramón y Cajal Researcher, later being promoted to I3 Researcher in 2011 at the same institution. In 2016, she joined the National Center for Microbiology at the Carlos III Health Institute (Madrid) as a Distinguished Researcher. In 2018, she was promoted to Tenured Scientist at the same institution.
Her research has focused on the study of humoral immunity against HIV-1 and the development of preventive HIV-1 vaccine prototypes. She is currently co-leading, alongside Dr. Víctor Sánchez Merino, the newly established Humoral Immunity and HIV Vaccines Unit.
-

Francisco Díez Fuertes
Investigador Doctor Indefinido
ORCID code: 0000-0003-2413-9229
Degree in Biology from the University of León, PhD specialized in molecular virology from the Complutense University of Madrid in 2010 and master's degree in bioinformatics and computational biology from the same university in 2012. He has done research stays at University of Illinois at Urbana Champaign (USA) in 2010, Nebraska Center for Virology (USA) in 2011, Institut Pasteur (France) in 2013 and J. Craig Venter Institute (USA) in 2015-2016.
He joined the AIDS Immunopathology Unit in 2013 with a contract from the “Sara Borrell” postdoctoral program. After a period at the August Pi i Sunyer Biomedical Research Institute in Barcelona he rejoins the AIDS Immunopathology Unit in 2020 as a PhD researcher.
His lines of research have focused on the genomic and transcriptomic characterization of extreme phenotypes in HIV-1 infection, including long-term non-progressors and elite controllers. He collaborates with other laboratories of the center in the analysis of outbreaks caused by viruses with interest in Public Health, as well as in evolutionary studies on genomic epidemiology. Since 2020 he has led different clinical studies on COVID-19. Currently, he combines omics sciences with different bioinformatics tools to answer different scientific questions in the field of virology, especially in HIV-1 and SARS-CoV-2 research. He currently coordinates together with Dr. Javier García Pérez the AIDS Immunopathology Unit.
-
María Pernas Escario
Senior Specialized Technician of Public Research Organizations (OPIs)
ORCID code: 0000-0003-2966-0160
-

Victor Sánchez Merino
Distinguished Scientist
ORCID code: 0000-0001-9400-427X
He holds a Bachelor's and a Ph.D. in Pharmacy from the Complutense University of Madrid, specializing in virology and molecular biology. His research has focused on the study of HIV and EBV. His doctoral thesis addressed the evolution of HIV-1 and the restoration of mutant HIV-1 reverse transcriptase function.
He completed a postdoctoral stay at Harvard University, investigating new viral interactions (2001–2003). At the University of Massachusetts, he explored CD8+ T lymphocyte responses in vertical HIV transmission (2003–2008).
In Spain, at the Hospital Clínico-IDIBAPS (Barcelona; 2008–2017) and the Carlos III Health Institute (Madrid; 2017–Present), he has led research on HIV-1 neutralizing antibodies and the design of preventive vaccines.He is currently co-leading, alongside Dr. Eloísa Yuste Herranz, the newly established Humoral Immunity and HIV Vaccines Unit. Additionally, he is a professor and principal investigator at Alfonso X el Sabio University (Madrid).
-

Nuria González Fernández
Investigadora Contratada indefinida
ORCID code: 0000-0002-0087-5144
She completed her PhD in 2007 (Universidad Autónoma de Madrid), focused on the development of an envelope recombinant virus system to characterize HIV-1 tropism, as well as on the study of the role of the chemokine CXCL12 in virus propagation at the infectious synapse. Part of this work was carried out in the laboratory of Dr. Quentin Sattentau at the University of Oxford.
During her postdoctoral period, she expanded her research on the mechanisms of HIV entry and specialized in the study of the neutralizing response. She developed a system to measure neutralizing activity, which has been used in clinical trials of HIV vaccine candidates. During a stay at the Vaccine Research Center, NIH (USA), she acquired experience in various techniques for the characterization of broadly neutralizing antibodies, leading to new collaborations and research projects, which she is currently developing in the AIDS Immunopathology Unit of the Carlos III Health Institute.
She has participated in research networks such as EAVI2020 (co-PI), CIBERINFEC, RIS and EUROPRISE (EU). Since 2014 she is a professor of the Master in Microbiology applied to Public Health and Infectious Diseases Research at the University of the University of Alcalá and, since 2023, of the Master in Human Immunodeficiency Virus Infection at the University Rey Juan Carlos.
-

Almudena Rubio Perez
Research Assistant
ORCID code: 0009-0006-4687-7555
Graduated in Biochemistry from the University of Córdoba (Andalusia, Spain) with a master's degree in Biomedicine from the University of Cádiz (Andalusia, Spain). She is currently part of the Humoral Immunity and HIV Vaccines Unit (IHV) at the National Center for Microbiology (CNM) under a Youth Guarantee contract funded by the Community of Madrid and is pursuing a Ph.D. in the Microbiology and Parasitology program at the Complutense University of Madrid.
-
Virginia Sandonís Martín
Senior Specialized Technician of Public Research Organizations (OPIs)
ORCID code: 0000-0001-5762-7531
-
Mercedes Bermejo Herrero
Investigadora post-doctoral contratada
ORCID code: 0000-0001-9909-8578
Degree and PhD in Biological Sciences (Biochemistry and Molecular Biology) from the Autonoma University of Madrid. Her doctoral thesis studied the expression of CXCR4 and SDF-1/CXCL12 in lymphocytes and dendritic cells and their implications in HIV-1 infection.
She has completed internships in various laboratories: the Immunology Department of the Gregorio Marañón University Hospital in Madrid, the Research Center of the 12 de Octubre University Hospital in Madrid (where she was head of the flow cytometry service) and is currently at the CNM (National Research Center) of the Carlos III Health Institute.
Her research interests have focused on the study of HIV biology and its interaction with the immune system. She has currently participated in clinical trials, CombiVacs and ENE-Covid Senior, and in collaboration with Hipra.
-
Rosa Fuentes Fernández
Laboratory Technician
-

Rubén Ayala Suárez
Técnico Superior Especializado OPI
ORCID code: 0000-0002-1271-646.
Graduated in Biotechnology from the University of Cadiz (2015), Master in Microbiology of Infectious Diseases (2016) and PhD in Functional Biology from the University of Alcalá (2023). He carried out his PhD Thesis at the AIDS Immunopathology laboratory (CNM) on post-translational epigenetic mechanisms of natural control of HIV infection. In the same period, he completed a Diploma in Bioinformatics at Pablo de Olavide University (2021).
In 2023 he joined as a postdoctoral researcher in the HIV and AIDS research group at the August Pi i Sunyer Biomedical Research Institute (Barcelona), where he worked on the relationship of HIV and senescence until his incorporation as a Técnico Superior Especializado in the AIDS Immunopathology unit of the Spanish National Center of Microbiology (ISCIII) in 2025.
The main research projects in which he participates focus on resistance and natural control to HIV infection, as well as the evaluation of the immune response in vaccine trials, using mainly bioinformatics techniques focused on massive sequencing (RNA-Seq, single-cell, genome sequencing), the application of biostatistics and machine learning in data management.
-
-

Almudena Cascajero Díaz
Técnico de laboratorio
ORCID code: 0000-0002-9654-3100
Técnico Superior de Actividades Técnicas y Profesionales (Unidades de Inmunopatología del SIDA y Legionella, Centro Nacional de Microbiología). Clinical Diagnostic Laboratory Technician by IES Renacimiento de Madrid.
Experience in cloning techniques and characterization of neutralizing antibodies and participation in different projects on the pathogenesis of HIV by studying the viral envelope and the mechanisms of resistance to antiretroviral drugs. This experience has subsequently allowed me to participate in 5 multicenter clinical studies studying the immune response against different variants of SARS-CoV-2.
Since 2021, I also participate as a laboratory technician in the Legionella Unit as a support to the Spanish National Health System through the microbiological surveillance of the disease to contribute to the prevention and control of legionellosis.
-

Manuela Beltrán Vicente
Técnico de Laboratorio Indefinido
ORCID code: 0000-0001-6185-2280
Senior Technician of Technical and Professional Activities (AIDS Immunopathology Unit, Spanish National Center of Microbiology).
Clinical Analysis Laboratory Specialist Technician by IES Las Musas (Madrid, 1996). Demonstrated experience in the development of strategies against HIV, focused on the screening of compounds of both natural and synthetic origin with antiviral activity and identification and evaluation of potential therapeutic agents, as well as the screening of serological samples for the study of immunity for the identification of possible strategies for the development of vaccines against HIV. -

Silvia Jara Herrera
Técnico de Laboratorio Contratado CIBERINFEC
ORCID code: 0009-0001-2842-2040
Clinical and Biomedical Diagnostic Laboratory Technician.
She is currently working in the AIDS Immunopathology Unit of the Spanish National Center of Microbiology (ISCIII) with a contract through the Spanish Biomedical Research Networking Centre in Infectious Diseases (CIBER-INFEC).
She worked from March 2020 to September 2024 at the Department of Animal Health (Faculty of Veterinary Medicine) of the Universidad Complutense de Madrid.
She has experience in serological techniques (ELISA, Western Blot and IFA), cell culture and molecular biology.
-

Irene Díaz Marín
Técnico de laboratorio contratado
Clinical and Biomedical Diagnostics laboratory technician by CIFP Politécnico de Murcia-CESUR and graduated in Journalism from the Complutense University of Madrid.
She is currently at the AIDS Immunopathology Unit of the Spanish National Center of Microbiology with a contract of the “Garantía Juvenil” program (Community of Madrid), where she performs technical tasks in several research projects about HIV-1 and COVID-19.
-

Lorena Vigón Hernandez
Tenured Specialized Technician from OPIs
ORCID code: 0000-0002-6405-4054
Graduate in Health Biology and PhD in Health Sciences from the University of Alcalá de Henares. In 2016, she joined the CNM-ISCIII under a Youth Guarantee contract funded by the Community of Madrid, and in 2018 she was awarded a pFIS fellowship, which enabled her to remain at the same institution. Subsequently, in 2022, she was appointed as a Tenured Specialized Technical Staff of the Spanish Public Research Organizations (OPIs).
Her research has primarily focused on elucidating the mechanism of action of tyrosine kinase inhibitors in HIV-1 infection (PMID: 32828803; PMID: 34186065), as well as on the identification of biomarkers that could predict COVID-19 severity (PMID: 34616404; PMID: 34122423; PMID: 35960731).
She is currently a member of the recently established Humoral Immunity and HIV Vaccines Unit, led by Dr. Eloisa Yuste and Dr. Victor Sanchez-Merino.
Actualmente forma parte de la recientemente creada Unidad de Inmunidad Humoral y Vacunas frente al VIH, liderada por la Dra. Eloísa Yuste Herranz y el Dr. Víctor Sánchez Merino.
-
Laura Capa Muñoz
Investigadora post-doctoral contratada
ORCID code: 0000-0002-0234-331X
Degree in Biological Sciences from the Universidad Autónoma de Madrid and PhD from the Universidad Complutense de Madrid, she has a master's degree in AIDS (Universidad Complutense de Madrid) and a master's degree in HIV infection (Universidad Rey Juan Carlos de Madrid).
Professional activity developed mainly in the study of infectious diseases, both in the field of basic research in public research centers and in the pharmaceutical industry, as well as in the field of public health and scientific management. She has worked in the international response to the HIV pandemic, representing the Ministry of Health as an expert in meetings of the European Commission and collaborated with the WHO. At the Instituto de Salud Carlos III, she has led the scientific management of national and European projects in the AIDS Immunopathology Unit and has been part of the Institute's Data Protection Working Group. Currently, she continues to coordinate the Cohort of Long-Term Non-Progressing Patients created by the Spanish AIDS Research Network (RIS), is part of the coordination team of the PhD Program in Biomedical Sciences and Public Health IMIENS-UNED-ISCIII and of the Institute's Working Group on Equality.
List of staff
Additional Information
The main objective of the Serology Laboratory is to provide services to centers of the National Health System, through the offer in the service portfolio of the National Microbiology Center, in carrying out diagnosis and reference through the detection of antibodies, both for primary diagnosis and for reference activities.
For this, it has the appropriate serological methodologies, many of them accredited by ENAC in accordance with the ISO15189 standard. Conducts test validation studies through collaboration agreements with private entities.
Participates in seroprevalence studies, carried out through management assignments with the Ministry of Health and with the Public Health authorities of different autonomous communities.
On the other hand, it participates in research projects in relation to infectious diseases, in recent years on neurological diseases, on emerging diseases and on the viruses included in the MMR vaccine.
The main objective of the Serology Laboratory is to provide services to centers of the National Health System, through the offer in the service portfolio of the National Microbiology Center, in carrying out diagnosis and reference through the detection of antibodies, both for primary diagnosis and for reference activities.
For this, it has the appropriate serological methodologies, many of them accredited by ENAC in accordance with the ISO15189 standard. Conducts test validation studies through collaboration agreements with private entities.
Participates in seroprevalence studies, carried out through management assignments with the Ministry of Health and with the Public Health authorities of different autonomous communities.
On the other hand, it participates in research projects in relation to infectious diseases, in recent years on neurological diseases, on emerging diseases and on the viruses included in the MMR vaccine.